Preoperative MRI and CA19-9 for predicting occult lymph node metastasis in small pancreatic ductal adenocarcinoma (≤ 2 cm)

术前MRI和CA19-9用于预测小胰腺导管腺癌(≤ 2 cm)的隐匿性淋巴结转移

阅读:1

Abstract

AIM: Accurate prediction of occult lymph node metastasis (OLNM) in small pancreatic ductal adenocarcinoma (sPDAC) (≤ 2 cm) is crucial for curative management. This study aims to explore clinical and MRI features associated with OLNM in sPDAC and their pathological and prognostic implications. MATERIALS AND METHODS: This retrospective study included 135 patients with pathologically confirmed sPDAC who underwent surgery between September 2014 and September 2023. Preoperative multi-sequence MRI, clinical data, and pathological features were analyzed. Univariate and multivariate logistic regression models were used to identify risk predictors of OLNM in sPDAC. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic performance and Kaplan-Meier survival analysis was used to evaluate prognostic outcomes. RESULTS: OLNM was present in 43 (31.9%) sPDAC patients. Univariate and multivariate analysis identified elevated CA19-9 (> 100 U/mL) (OR = 2.404, P = 0.040) and low apparent diffusion coefficient (ADC) values (OR = 0.243, P = 0.031) as independent predictors of OLNM. The combined clinical-radiological model demonstrated an AUC of 0.740, significantly higher than CA19-9 (AUC = 0.653, P = 0.021) or ADC alone (AUC = 0.635, P = 0.035). sPDAC patients with OLNM exhibited higher rates of lymphovascular invasion (44.2%, P = 0.013) and pathological fat invasion (86.0%, P = 0.030). OLNM was associated with significantly worse OS and DFS (P = 0.034 and 0.043). CONCLUSIONS: OLNM is associated with adverse pathological features and poorer prognosis. The combination of preoperative MRI assessment of ADC and CA19-9 may aid in identifying sPDAC patients at high risk for OLNM. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。